



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2000 Certified Company

CIN No.: L24239MH1988PLC047759

SYNCOM/SE/2025-26

12th November, 2025

Online filing at: www.listing.bseindia.com and
<https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp>

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai (M.H.) 400 001
BSE CODE:524470

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400051
NSE SYMBOL: SYNCOMF

Subject: Regulation 33(3) of SEBI (LODR) Regulations, 2015 - Submission of Standalone & Consolidated unaudited Financial Results along with Limited Review Report, Statement of Assets and Liabilities and Cash Flow for the quarter and half year ended on 30th September, 2025.

Dear Sir/Ma'am

This is in continuation of our letter no. **SYNCOM/SE/2025-26** dated 7th November, 2025 regarding intimation of Board meeting for consideration and approval of Standalone and Consolidated Un-Audited Financial Results for the Quarter/ Half Year ended 30th September, 2025.

Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the following:

1. Standalone and Consolidated Un-Audited Financial Results of the Company for the Quarter/ Half Year ended on 30th September, 2025;
2. Standalone and Consolidated Limited Review Report by the Statutory Auditors of the company for the Quarter/ Half Year ended on 30th September, 2025;
3. Standalone and Consolidated Un-Audited Statement of Assets and Liabilities for the Half Year ended on 30th September, 2025; and
4. Standalone and Consolidated Un-Audited Statement of Cash Flow for the Half year ended on 30th September, 2025.

The aforesaid results were **considered and approved by the Board of Directors** at its meeting held on **Wednesday, 12th November, 2025**, which **commenced at 3:00 P.M. and concluded at 5:00 P.M**

We are also in process of filing the aforesaid financial results in XBRL format within the stipulated time and the same shall also be hosted on the website of the company in due course.

Further, the Financial Results will be published in widely circulated English and Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.

You are requested to kindly take the unaudited Financial Results, Statement of Assets and Liabilities and Cash Flow along with Limited Review Report, on record for your reference and record.

Thanking You,
Yours Faithfully,

For, SYNCOM FORMULATIONS (INDIA) LIMITED

CS VAISHALI AGRAWAL
COMPANY SECRETARY &
COMPLIANCE OFFICER

Encl: a/a

Bringing a smile on every face...

Regd. Off. : 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), MUMBAI-400 093, INDIA, Tel.: 91-022-30887744-54, Fax: 91-022-30887755, Email: sfil87@syncomformulations.com

Works : 256-257, Sector-I, PITHAMPUR, Dist.-Dhar, M.P. - 454 775, INDIA, Tel.: 91-07292-403122, 407039, Fax: 91-07292-253404, Email: assistant2@sfil.in

Corp. Off. : 207, Saket Nagar, Near Saket Club, INDORE - 452 018, INDIA. Tel. : 91-0731-2700458, Email : finance@sfil.in

Website : <http://www.sfil.in>



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Plithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759


STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTERLY AND HALF YEARLY ENDED 30TH SEPTEMBER, 2025

(Rs. In Lakhs) (Except EPS)

S. No.	Particulars	Quarter Ended			Year to date Ended		Year Ended
		30/09/2025	30/06/2025	30/09/2024	30/09/2025	30/09/2024	31/03/2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	12143.51	11654.69	10149.25	23798.20	18735.68	46284.93
2	Other Income	523.44	601.97	418.35	1125.41	646.32	1719.12
3	Total Income (1 + 2)	12666.95	12256.66	10567.60	24923.61	19382.00	48004.05
4	EXPENSES						
	(a) Cost of materials consumed	4642.63	5961.30	6857.57	10603.93	12160.70	27802.93
	(b) Purchases of Stock-in-Trade	1535.33	1561.93	1260.24	3097.26	1666.32	3947.71
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	909.36	(616.39)	(1560.83)	292.97	(1824.12)	(1062.24)
	(d) Employee benefits expense	1673.08	1595.44	1240.39	3268.52	2325.15	5217.37
	(e) Finance costs	25.03	23.74	16.22	48.77	54.87	85.02
	(f) Depreciation and amortization expense	135.00	134.00	130.00	269.00	260.00	519.39
	(g) Other expenses	1510.77	1574.94	1158.89	3085.71	2264.27	5028.63
	Total expenses (4)	10431.20	10234.96	9102.48	20666.16	16907.19	41538.81
5	Profit/(loss) before exceptional items and tax (3- 4)	2235.75	2021.70	1465.12	4257.45	2474.81	6465.24
6	Exceptional Items	0.00	4.13	(0.24)	4.13	(0.24)	0.58
7	Profit/(loss) before tax (5 - 6)	2235.75	2025.83	1464.88	4261.58	2474.57	6465.82
8	Tax expense:						
	(1) Current tax	522.00	431.60	348.55	953.60	592.32	1445.26
	(2) Deferred tax	29.64	21.30	21.33	50.94	24.39	133.38
9	Profit (Loss) for the period from continuing operations (7- 8)	1684.11	1572.93	1095.00	3257.04	1857.86	4887.18
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9 + 12)	1684.11	1572.93	1095.00	3257.04	1857.86	4887.18
14	Other Comprehensive Income						
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	(5.58)	403.84	391.88	398.26	667.81	458.02
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	1678.53	1976.77	1486.88	3655.30	2525.67	5345.20
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves	-	-	-	-	-	24590.38
18	Earnings per equity share (for continuing operation):						
	(1) Basic	0.18	0.21	0.16	0.39	0.27	0.57
	(2) Diluted	0.18	0.21	0.16	0.39	0.27	0.57
19	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)						
	(1) Basic	0.18	0.21	0.16	0.39	0.27	0.57
	(2) Diluted	0.18	0.21	0.16	0.39	0.27	0.57

Place: Indore

Date: 12/11/2025



For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda

Chairman & Wholetime Director

Din : 02359461

**SYNCOM FORMULATIONS (INDIA) LIMITED**

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works :- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND HALF YEARLY UNAUDITED RESULTS


S. No.	Particulars	Quarter Ended			Year to date Ended		Previous Year Ended
		30/09/2025	30/06/2025	30/09/2024	30/09/2025	30/09/2024	31/03/2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	a) Pharmaceuticals Drugs & Formulations	12567.69	12062.52	10218.43	24630.21	18803.76	46,784.92
	b) Trading of Commodities	0.00	104.56	251.10	104.56	383.51	825.84
	c) Renting of Property	99.26	89.58	98.07	188.84	194.73	393.29
	Total Segment Revenue	12666.95	12256.66	10567.60	24923.61	19382.00	48,004.05
	Less: Inter Segment Revenue	0.00	0.00	0.00	-	-	-
	Revenue from Operations	12666.95	12256.66	10567.60	24923.61	19382.00	48,004.05
2	Segment Results Profit(+)/Loss(-) before tax and interest from each segment						
	a) Pharmaceuticals Drugs & Formulations	2167.52	1960.52	1382.69	4128.04	2338.05	6,169.90
	b) Trading of Commodities	0.00	1.35	8.40	1.35	12.79	20.35
	c) Renting of Property	93.26	83.57	90.01	176.83	176.60	360.59
	Total Profit before tax	2260.78	2045.44	1481.10	4306.22	2529.44	6,550.84
	Less: i) Interest	25.03	23.74	16.22	48.77	54.87	85.02
	ii) Other Un-allocable Expenditure	0.00	0.00	0.00	0.00	-	-
	Profit before tax	2235.75	2021.70	1464.88	4257.45	2474.57	6,465.82
3	(Segment Asset-Segment Liabilities)						
	Segment Asset						
	a) Pharmaceuticals Drugs & Formulations	40128.78	39302.09	31234.08	40128.78	31234.08	35,752.01
	b) Trading of Commodities	251.35	259.18	971.86	251.35	971.86	448.67
	c) Renting of Property	4733.44	4733.44	4733.45	4733.44	4733.45	4,767.98
	Total Segment Asset	45113.57	44294.71	36939.39	45113.57	36939.39	40,968.66
	Un-allocable Assets	0.00	0.00	0.00	-	-	-
	Net Segment Asset	45113.57	44294.71	36939.39	45113.57	36939.39	40,968.66
	Segment Liabilities						
	a) Pharmaceuticals Drugs & Formulations	7332.38	8185.83	5432.16	7332.38	5432.16	6,754.47
	b) Trading of Commodities	2.11	8.36	243.87	2.11	243.87	82.76
	c) Renting of Property	133.40	133.36	92.52	133.40	92.52	141.04
	Total Segment Liabilities	7467.89	8327.55	5768.55	7467.89	5768.55	6,978.27
	Un-allocable Liabilities	0.00	0.00	0.00	-	-	-
	Net Segment Liabilities	7467.89	8327.55	5768.55	7467.89	5768.55	6,978.27

Notes:-

- 1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12/11/2025.
- 2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- 3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
- 4 The Standalone Statement of Assets and Liabilities as at 30th September, 2025 and the Standalone Statement of Cash Flow is provided as an annexure to this statement.
- 5 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th September 2025. The report does not have any impact on the above results and notes which needs explanation.
- 6 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.

Place: Indore

Date: 12/11/2025



For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda

Chairman & Wholetime Director

Din : 02359461

**SYNCOM FORMULATIONS (INDIA) LIMITED**

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

Standalone Statement of Assets & Liabilities as at 30/09/2025

Particulars	Rs. In Lacs	30/09/2025 unaudited	31/03/2025 Audited
ASSETS			
Non-current assets			
(a) Property, Plant and Equipment		7,669.64	7,752.61
(b) Capital Work in Progress		800.95	-
(c) Intangible assets		4.72	4.72
(d) Investment Property		4,733.44	4,733.44
(e) Financial Assets			
(i) Investments		385.26	364.82
(ii) Fixed Deposits & Accrued Interest		1,489.76	1,218.67
(iii) Deposits		72.26	66.62
(f) Other Non Current Assets		71.00	81.58
Current assets			
(a) Inventories		2,845.77	4,129.29
(b) Financial Assets			
(i) Investments		14,381.89	8,921.64
(ii) Trade Receivables		10,063.40	10,694.43
(iii) Cash And Cash Equivalents		23.66	69.23
(iv) Bank Balances other than (iii) above		-	-
(v) Deposits		367.35	353.22
(vi) Loans & Advances		617.69	539.29
(d) Other Current Assets		1,586.78	2,039.10
Total		45,113.57	40,968.66
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share Capital		9,400.00	9,400.00
(b) Other Equity		28,245.68	24,590.38
Liabilities			
Non Current Liabilities			
(a) Financial Liabilities			
(i) Trade and other Deposits		133.40	133.35
(b) Provisions		459.38	416.84
(c) Deferred Tax Liabilities (Net)		681.99	631.05
Current liabilities			
(a) Financial liabilities			
(i) Borrowings		29.96	404.32
(ii) Trade Payables			
Total Outstanding Dues of Micro Enterprises and Small Enterprises		667.37	2,278.89
Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises		3,761.27	1,993.30
(iii) Other Financial Liabilities		212.75	213.00
(b) Other Current Liabilities		860.49	495.68
(c) Provisions		661.28	411.85
Total		45,113.57	40,968.66

Place: Indore
Date: 12/11/2025

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda

Chairman & Wholetime Director

Din : 02359461





Syncom Formulations (India) Limited

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

Standalone Cash Flow Statement for the period ended September 30, 2025

Decrease In CA & Increase in CL: Add
Increase in CA & Decrease in CL: Deduct

Particulars	30/09/2025 Amount	31/03/2025 Amount
Cash Flow from Operating Activities		
Profit before extraordinary item and tax	4,257.45	6,465.24
Adjustments for:		
Gain on Sale of Machinery / (Loss on Sale of Vehicle)	-	0.58
Gain/(Loss) on Actuarial valuation of employee benefits	(6.20)	(28.91)
Depreciation	269.00	519.39
Depreciation Written Back	-	(39.14)
Finance Costs	48.77	85.02
Other Income	(1,092.70)	(1,633.53)
Operating Profit before working capital changes	3,476.32	5,368.65
Changes in Working Capital		
Inventory	1,283.52	(2,021.14)
Trade Receivables	631.03	(1,372.97)
Loans & Advances	(78.40)	(109.96)
Other Current Assets	438.19	(1,140.49)
Trade Payables	156.45	2,849.09
Other Financial Liabilities	(0.25)	(0.62)
Other Current Liabilities	364.81	137.64
Short Term Provisions	249.43	66.39
Changes in Working Capital	3,044.78	(1,592.06)
Cash Generated from Operations before Tax	6,521.10	3,776.59
Less: Income Tax Paid	953.60	1,445.26
Net Cash From Operating Activities	5,567.50	2,331.33
Cash Flow from Investing Activities		
Change in Property Plant and Equipment, Intangible Assets and Capital Work in Progress	(982.85)	(995.93)
Change in Investment Property	-	-
Change in Fixed Deposit & Accrued Interest	(271.09)	(183.82)
Change in Deposits	(5.64)	(14.72)
Change in Other Non Current Assets	10.58	(61.02)
Change in Trade & Other Deposits	0.05	(38.25)
Other Income	1,092.70	1,633.53
Change in Investment	(5,076.23)	(2,177.67)
Net Cash from Investing Activities	(5,232.48)	(1,837.88)
Cash Flow from Financing Activities		
Finance Costs	(48.77)	(85.02)
Change in Long Term Liabilities	42.54	86.46
Issue of Warrants & Share capital	-	-
Dividend Paid	-	-
Borrowings	(374.36)	(6,760.71)
Net Cash from Financing Activities	(380.59)	(6,759.27)
Net Decrease in Cash & Cash Equivalents	(45.57)	(6,265.82)
Cash & Cash Equivalents at the beginning of the Period	69.23	6,335.05
Cash & Cash Equivalents at the End of Period	23.66	69.23

Place: Indore


Date: 12/11/2025

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda

Chairman & Wholetime Director

Din : 02359461



Limited Review Report on Un-audited Standalone Financial Results for the Quarter & Half year ended 30th September, 2025 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)


We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED ("the Company")**, for the period ended September, 30, 2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta & Associates
Chartered Accountants
FRN: 011524C



CA Manish Mittal
(Partner)

M. No. 079452

UDIN: 25079452BMIHEC3730



Place: Indore
Date: 12 November, 2025

**SYNCOM FORMULATIONS (INDIA) LIMITED**

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist. Dhar-464775


E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTERLY AND HALF YEARLY ENDED 30TH SEPTEMBER, 2025

S. No.	Particulars	Quarter Ended			Year to date ended		Year Ended
		30-09-2025 Unaudited	30-06-2025 Unaudited	30-09-2024 Unaudited	30-09-2025 Unaudited	30-09-2024 Unaudited	31-03-2025 *Audited
1	Revenue from Operations	12171.74	11690.17	10231.42	23861.91	18860.30	46501.26
2	Other Income	525.05	603.47	414.92	1128.52	645.42	1743.40
3	Total Income (1 + 2)	12696.79	12293.64	10646.34	24990.43	19505.72	48244.66
4	EXPENSES						
	(a) Cost of materials consumed	4642.63	5961.30	6857.57	10603.93	12160.70	27802.93
	(b) Purchases of Stock-in-Trade	1529.13	1568.13	1266.24	3097.26	1694.85	3996.75
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	903.71	(612.48)	(1543.72)	291.23	(1824.12)	(1066.15)
	(d) Employee benefits expense	1673.08	1595.44	1240.39	3268.52	2325.15	5217.37
	(e) Finance costs	26.49	25.08	15.96	51.57	54.99	86.49
	(f) Depreciation and amortization expense	135.00	134.00	130.00	269.00	260.00	519.39
	(g) Other expenses	1583.10	1597.06	1194.83	3180.16	2338.87	5137.19
	Total expenses (4)	10493.14	10268.53	9161.27	20761.67	17010.44	41693.97
5	Profit/(loss) before exceptional items and tax (3- 4)	2203.65	2025.11	1485.07	4228.76	2495.28	6550.69
6	Exceptional Items	0.00	4.13	0.00	4.13	(0.24)	0.58
7	Profit/(loss) before tax (5 - 6)	2203.65	2029.24	1485.07	4232.89	2495.04	6551.27
8	Tax expense:						
	(1) Current tax	513.90	432.50	352.92	946.40	596.82	1474.43
	(2) Deferred tax	29.64	21.30	21.33	50.94	24.39	133.38
9	Profit (Loss) for the period from continuing operations (7-8)	1660.11	1575.44	1110.82	3235.55	1873.83	4943.46
10	Profit/(loss) from discontinued operations		0.00	0.00		0.00	0.00
11	Tax expense of discontinued operations		0.00	0.00		0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)		0.00	0.00		0.00	0.00
13	Profit/(loss) for the period (9 + 12)	1660.11	1575.44	1110.82	3235.55	1873.83	4943.46
14	Other Comprehensive Income						
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00		0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00		0.00	0.00
	B (i) Items that will be reclassified to profit or loss	(5.58)	403.84	391.88	398.26	667.81	458.02
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00		0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	1654.53	1979.28	1502.70	3633.81	2541.64	5401.48
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves						24815.76
18	Earnings per equity share (for continuing operation):						
	(1) Basic	0.18	0.21	0.16	0.39	0.27	0.57
	(2) Diluted	0.18	0.21	0.16	0.39	0.27	0.57
19	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)						
	(1) Basic	0.18	0.21	0.16	0.39	0.27	0.57
	(2) Diluted	0.18	0.21	0.16	0.39	0.27	0.57

Place: Indore

Date: 12/11/2025



For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda
Chairman & Wholetime Director
Din : 02359461

**SYNCOM FORMULATIONS (INDIA) LIMITED**

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works :- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775


E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND HALF YEARLY UNAUDITED RESULTS

S. No.	Particulars	Quarter Ended			Year to date ended		Year Ended
		30-09-2025 Unaudited	30-06-2025 Unaudited	30-09-2024 Unaudited	30-09-2025 Unaudited	30-09-2024 Unaudited	31-03-2025 *Audited
1	Segment Revenue						
	a) Pharmaceuticals Drugs & Formulations	12,597.98	12,099.95	10,298.07	24697.93	18928.38	47,027.33
	b) Trading of Commodities	-	104.56	251.10	104.56	383.51	825.84
	c) Renting of Property	98.81	89.13	97.17	187.94	193.83	391.49
	Total Segment Revenue	12,696.79	12,293.64	10,646.34	24,990.43	19,505.72	48,244.66
	Less: Inter Segment Revenue			-		0.00	-
	Revenue from Operations	12,696.79	12,293.64	10,646.34	24,990.43	19,505.72	48,244.66
2	Segment Results Profit(+)/Loss(-) before tax and interest from each segment						
	a) Pharmaceuticals Drugs & Formulations	2,131.33	1,965.72	1,403.29	4097.05	2359.54	6,258.62
	b) Trading of Commodities	0.00	1.35	8.40	1.35	12.79	20.35
	c) Renting of Property	98.81	83.12	89.11	181.93	177.70	358.79
	Total Profit before tax	2,230.14	2,050.19	1,500.80	4,280.33	2,550.03	6,637.76
	Less: i) Interest	26.49	25.08	15.96	51.57	54.99	86.49
	ii) Other Un-allocable Expenditure			-		0.00	-
	Profit before tax	2,203.65	2,025.11	1,484.84	4,228.76	2,495.04	6,551.27
3	(Segment Asset-Segment Liabilities)						
	Segment Asset						
	a) Pharmaceuticals Drugs & Formulations	40,623.55	39,780.77	31,539.20	40623.55	31539.20	36,111.42
	b) Trading of Commodities	251.35	259.18	971.86	251.35	971.86	448.67
	c) Renting of Property	4,733.44	4,733.44	4,733.45	4733.44	4733.45	4,767.98
	Total Segment Asset	45,608.34	44,773.39	37,244.51	45,608.34	37,244.51	41,328.07
	Un-allocable Assets			-		0.00	-
	Net Segment Asset	45,608.34	44,773.39	37,244.51	45,608.34	37,244.51	41,328.07
	Segment Liabilities						
	a) Pharmaceuticals Drugs & Formulations	7,623.26	8,436.63	5,552.20	7623.26	5552.20	6,888.49
	b) Trading of Commodities	2.11	8.36	243.87	2.11	243.87	82.76
	c) Renting of Property	133.40	133.36	92.52	133.40	92.52	141.04
	Total Segment Liabilities	7,758.77	8,578.35	5,888.59	7,758.77	5,888.59	7,112.29
	Un-allocable Liabilities			-		0.00	-
	Net Segment Liabilities	7,758.77	8,578.35	5,888.59	7,758.77	5,888.59	7,112.29

Notes:-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12/11/2025
- These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th September, 2025. The report does not have any impact on the above results and notes which needs explanation.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- The Company currently have 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd., Sante Biotech Pvt. Ltd. And Vindit Biotech International Pvt. Ltd.
- The Consolidated Statement of Assets and Liabilities as at 30th September, 2025 and Consolidated Statement of Cash Flow is provided as an annexure to this statement

Place: Indore
Date: 12/11/2025

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda
Chairman & Wholetime Director
Din : 02359461

**SYNCOM FORMULATIONS (INDIA) LIMITED**

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED Statement of Assets & Liabilities as at 30/09/2025

Particulars	30/09/2025	31/03/2025
Rs. In Lacs	Unaudited	*Audited
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	7,669.64	7,752.61
(b) Capital Work in Progress	800.95	-
(c) Intangible assets	4.72	4.72
(d) Investment Property	4,733.44	4,733.44
(e) Financial Assets		-
(i) Investments	382.26	361.82
(ii) Fixed Deposits & Accrued Interest	1,505.22	1,330.52
(iii) Deposits	72.26	66.62
(f) Other Non Current Assets	71.00	81.58
Current assets		
(a) Inventories	2,851.42	4,133.20
(b) Financial Assets		-
(i) Investments	14,381.89	8,921.64
(ii) Trade Receivables	10,224.22	10,754.85
(iii) Cash And Cash Equivalents	27.53	71.20
(iv) Bank Balances other than (iii) above	100.00	-
(v) Deposits	367.35	353.22
(vi) Loans & Advances	624.53	543.53
(d) Other Current Assets	1,791.91	2,219.12
Total	45,608.34	41,328.07
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	9,400.00	9,400.00
(b) Other Equity	28,449.57	24,815.76
Liabilities		
Non Current Liabilities		
(a) Financial Liabilities		-
(i) Trade and other Deposits	133.40	133.35
(b) Provisions	459.38	416.84
(c) Deferred Tax Liabilities (Net)	681.99	631.05
Current liabilities		
(a) Financial liabilities		-
(i) Borrowings	69.70	458.36
(ii) Trade Payables		-
Total Outstanding Dues of Micro Enterprises and Small Enterprises	667.37	2,281.33
Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises	3,963.42	1,998.41
(iii) Other Financial Liabilities	212.74	213.00
(b) Other Current Liabilities	911.67	561.62
(c) Provisions	659.10	418.35
Total	45,608.34	41,328.07

Place: Indore
Date: 12/11/2025

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda

Chairman & Wholetime Director

Din : 02359461



Syncom Formulations (India) Limited

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

Consolidated Cash Flow Statement for the period ended 30th September 2025

Decrease In CA & Increase in CL: Add

Increase in CA & Decrease in CL: Deduct

(Rs. In Lacs)

Particulars	30/09/2025 Amount	31/03/2025 Amount
Cash Flow from Operating Activities		
Profit before extraordinary item and tax	4,228.76	6,550.69
Adjustments for:		
Gain on Sale of Machinery / (Loss on Sale of Vehicle)	-	0.58
Gain/(Loss) on Actuarial valuation of employee benefits	(6.20)	(28.91)
Depreciation	269.00	519.39
Depreciation Written Back	-	(39.14)
Finance Costs	51.57	86.49
Other Income	(1,095.81)	(1,657.81)
Operating Profit before working capital changes	3,447.32	5,431.29
Changes in Working Capital		
Inventory	1,281.78	(2,025.05)
Trade Receivables	530.63	(425.01)
Loans & Advances	(81.00)	(115.75)
Other Current Assets	427.21	(1,116.35)
Trade Payables	351.05	1,865.35
Other Financial Liabilities	(0.26)	(0.62)
Other Current Liabilities	350.05	148.92
Short Term Provisions	240.75	55.26
Changes in Working Capital	3,100.21	(1,613.25)
Cash Generated from Operations before Tax	6,547.53	3,818.04
Less: Income Tax Paid	946.40	1,474.43
Net Cash From Operating Activities	5,601.13	2,343.61
Cash Flow from Investing Activities		
Change in Property Plant and Equipment, Intangible Assets and Capital Work in Progress	(982.85)	(995.93)
Change in Fixed Deposit & Accrued Interest	(274.70)	(190.64)
Change in Deposits	(14.13)	(14.72)
Change in Other Non Current Assets	10.58	(61.02)
Change in Trade & Other Deposits	(5.64)	(38.25)
Other Income	1,095.81	1,657.81
Change in Investment	(5,076.23)	(2,177.67)
Net Cash from Investing Activities	(5,247.16)	(1,820.42)
Cash Flow from Financing Activities		
Finance Costs	(51.57)	(86.49)
Change in Long Term Liabilities	42.59	86.46
Borrowings	(388.66)	(6,790.30)
Net Cash from Financing Activities	(397.64)	(6,790.33)
Net Decrease in Cash & Cash Equivalents	(43.67)	(6,267.14)
Cash & Cash Equivalents at the beginning of the Period	71.20	6,338.34
Cash & Cash Equivalents at the End of Period	27.53	71.20

Place: Indore

Date: 12/11/2025



For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda
Chairman & Wholtime Director
Din : 02359461

Limited Review Report on Un-audited Consolidated Financial Results for the Quarter and Half Year ended 30th September, 2025 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ended September 30, 2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.
2. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entity:

S. No.	Name of the Company	Relationship with the Holding Company
1.	Sante Biotech Pvt. Ltd.	Wholly Owned Subsidiary
2.	Synmex Pharma Pvt. Ltd.	Wholly Owned Subsidiary
3.	Vincit Biotech International Pvt. Ltd.	Wholly Owned Subsidiary




5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore

Date: 12th November, 2025

For, Sanjay Mehta & Associates
Chartered Accountants

FRN: 011524C


CA Manish Mittal
(Partner)

M. No. 079452

UDIN: 25079452BMIHED1311

